REFERENCES
1. der Bliek AM, Sedensky MM, Morgan PG. Cell biology of the mitochondrion. Genetics 2017;207:843-71.
2. Keogh MJ, Chinnery PF. Mitochondrial DNA mutations in neurodegeneration. Biochim Biophys Acta 2015;1847:1401-11.
3. Baines HL, Stewart JB, Stamp C, et al. Similar patterns of clonally expanded somatic mtDNA mutations in the colon of heterozygous mtDNA mutator mice and ageing humans. Mech Ageing Dev 2014;139:22-30.
4. Simsek D, Furda A, Gao Y, et al. Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair. Nature 2011;471:245-8.
5. Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 2012;13:659-71.
7. Tan J, Wagner M, Stenton SL, et al. Lifetime risk of autosomal recessive mitochondrial disorders calculated from genetic databases. EBioMedicine 2020;54:102730.
8. Frazier AE, Thorburn DR, Compton AG. Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology. J Biol Chem 2019;294:5386-95.
9. Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Orekhov AN. Mitochondrial lipid homeostasis at the crossroads of liver and heart diseases. Int J Mol Sci 2021;22:6949.
10. Dabravolski SA, Bezsonov EE, Orekhov AN. The role of mitochondria dysfunction and hepatic senescence in NAFLD development and progression. Biomed Pharmacother 2021;142:112041.
11. Dabravolski SA, Bezsonov EE, Baig MS, et al. Mitochondrial mutations and genetic factors determining NAFLD risk. Int J Mol Sci 2021;22:4459.
12. Dabravolski SA, Nikiforov NG, Eid AH, et al. Mitochondrial dysfunction and chronic inflammation in polycystic ovary syndrome. Int J Mol Sci 2021;22:3923.
13. Dabravolski SA, Orekhova VA, Baig MS, et al. The role of mitochondrial mutations and chronic inflammation in diabetes. Int J Mol Sci 2021;22:6733.
14. Salnikova D, Orekhova V, Grechko A, et al. Mitochondrial dysfunction in vascular wall cells and its role in atherosclerosis. Int J Mol Sci 2021;22:8990.
15. Stenton SL, Prokisch H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine 2020;56:102784.
16. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Changes of mitochondria in atherosclerosis: possible determinant in the pathogenesis of the disease. Atherosclerosis 2013;227:283-8.
17. Gottlieb RA, Thomas A. Mitophagy and mitochondrial quality control mechanisms in the heart. Curr Pathobiol Rep 2017;5:161-9.
18. Gkikas I, Palikaras K, Tavernarakis N. The role of mitophagy in innate immunity. Front Immunol 2018;9:1283.
19. Liesa M, Palacín M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev 2009;89:799-845.
20. Mouli PK, Twig G, Shirihai OS. Frequency and selectivity of mitochondrial fusion are key to its quality maintenance function. Biophys J 2009;96:3509-18.
21. Chen G, Kroemer G, Kepp O. Mitophagy: an emerging role in aging and age-associated diseases. Front Cell Dev Biol 2020;8:200.
22. Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol 2018;20:1013-22.
23. Palikaras K, Lionaki E, Tavernarakis N. Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans. Nature 2015;521:525-8.
25. Pedro JM, Kroemer G, Galluzzi L. Autophagy and mitophagy in cardiovascular disease. Circ Res 2017;120:1812-24.
26. Mani S, Swargiary G, Chadha R. Mitophagy impairment in neurodegenerative diseases: Pathogenesis and therapeutic interventions. Mitochondrion 2021;57:270-93.
27. Borgia D, Malena A, Spinazzi M, et al. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. Hum Mol Genet 2017;26:1087-103.
28. Chen Z, Berquez M, Luciani A. Mitochondria, mitophagy, and metabolic disease: towards assembling the puzzle. Cell Stress 2020;4:147-50.
29. Xu Y, Shen J, Ran Z. Emerging views of mitophagy in immunity and autoimmune diseases. Autophagy 2020;16:3-17.
30. Denisenko TV, Gogvadze V, Zhivotovsky B. Mitophagy in carcinogenesis and cancer treatment. Discov Oncol 2021;12:58.
31. Yu-Wai-Man P, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet 2002;39:162-9.
32. Bargiela D, Chinnery PF. Mitochondria in neuroinflammation - multiple sclerosis (MS), leber hereditary optic neuropathy (LHON) and LHON-MS. Neurosci Lett 2019;710:132932.
33. Murakami H, Ono K. MELAS: mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes. Brain Nerve 2017;69:111-7.
34. Seitun S, Massobrio L, Rubegni A, et al. MELAS syndrome with cardiac involvement: a multimodality imaging approach. Case Rep Cardiol 2016;2016:1490181.
35. Pek NMQ, Phua QH, Ho BX, et al. Mitochondrial 3243A > G mutation confers pro-atherogenic and pro-inflammatory properties in MELAS iPS derived endothelial cells. Cell Death Dis 2019;10:802.
36. Chistiakov DA, Revin VV, Sobenin IA, Orekhov AN, Bobryshev YV. Vascular endothelium: functioning in norm, changes in atherosclerosis and current dietary approaches to improve endothelial function. Mini Rev Med Chem 2015;15:338-50.
37. Poznyak AV, Ivanova EA, Sobenin IA, Yet SF, Orekhov AN. The role of mitochondria in cardiovascular diseases. Biology (Basel) 2020;9:137.
38. Sobenin IA, Sazonova MA, Postnov AY, Salonen JT, Bobryshev YV, Orekhov AN. Association of mitochondrial genetic variation with carotid atherosclerosis. PLoS One 2013;8:e68070.
39. Sobenin IA, Zhelankin AV, Khasanova ZB, et al. Heteroplasmic variants of mitochondrial DNA in atherosclerotic lesions of human aortic intima. Biomolecules 2019;9:455.
40. Markin AM, Sobenin IA, Grechko AV, Zhang D, Orekhov AN. Cellular mechanisms of human atherogenesis: focus on chronification of inflammation and mitochondrial mutations. Front Pharmacol 2020;11:642.
41. Bezsonov EE, Sobenin IA, Orekhov AN. Immunopathology of atherosclerosis and related diseases: focus on molecular biology. Int J Mol Sci 2021;22:4080.
42. Mushenkova NV, Bezsonov EE, Orekhova VA, Popkova TV, Starodubova AV, Orekhov AN. Recognition of oxidized lipids by macrophages and its role in atherosclerosis development. Biomedicines 2021;9:915.
43. Mezentsev A, Bezsonov E, Kashirskikh D, Baig MS, Eid AH, Orekhov A. Proatherogenic sialidases and desialylated lipoproteins: 35 years of research and current state from bench to bedside. Biomedicines 2021;9:600.
44. Sobenin IA, Salonen JT, Zhelankin AV, et al. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value. Biomed Res Int 2014;2014:205697.
45. Myasoedova VA, Kirichenko TV, Melnichenko AA, et al. Anti-atherosclerotic effects of a phytoestrogen-rich herbal preparation in postmenopausal women. Int J Mol Sci 2016;17:1318.
46. Malekmohammad K, Bezsonov EE, Rafieian-Kopaei M. Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms. Front Cardiovasc Med 2021;8:707529.
47. Puteri MU, Azmi NU, Kato M, Saputri FC. PCSK9 promotes cardiovascular diseases: recent evidence about its association with platelet activation-induced myocardial infarction. Life (Basel) 2022;12:190.
48. Ding Z, Liu S, Wang X, et al. Cross-talk between pcsk9 and damaged mtDNA in vascular smooth muscle cells: role in apoptosis. Antioxid Redox Signal 2016;25:997-1008.
49. Mahboobnia K, Pirro M, Marini E, et al. PCSK9 and cancer: rethinking the link. Biomed Pharmacother 2021;140:111758.
50. Mitrofanov KY, Zhelankin AV, Shiganova GM, et al. Analysis of mitochondrial DNA heteroplasmic mutations A1555G, C3256T, T3336C, С5178А, G12315A, G13513A, G14459A, G14846А and G15059A in CHD patients with the history of myocardial infarction. Exp Mol Pathol 2016;100:87-91.
51. Hefti E, Blanco JG. Mitochondrial DNA heteroplasmy in cardiac tissue from individuals with and without coronary artery disease. Mitochondrial DNA A DNA Mapp Seq Anal 2018;29:587-93.
52. Elsharawy MA, Alkhadra AH, Ibrahim MF, et al. Impact of atherosclerosis risk factors on the clinical presentation of arterial occlusive disease in Arabic patients. Int J Angiol 2008;17:203-6.
53. Vilela EM, Fontes-Carvalho R. Inflammation and ischemic heart disease: The next therapeutic target? Rev Port Cardiol (Engl Ed) 2021;40:785-96.
54. Linton MF, Yancey PG, Davies SS, et al. The role of lipids and lipoproteins in atherosclerosis. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
55. Liu YX, Yuan PZ, Wu JH, Hu B. Lipid accumulation and novel insight into vascular smooth muscle cells in atherosclerosis. J Mol Med (Berl) 2021;99:1511-26.
56. Hilgendorf I, Swirski FK, Robbins CS. Monocyte fate in atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:272-9.
58. Gupta RM, Lee-Kim VS, Libby P. The march of monocytes in atherosclerosis: one cell at a time. Circ Res 2020;126:1324-6.
59. Chistiakov DA, Orekhov AN, Sobenin IA, Bobryshev YV. Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation. Front Physiol 2014;5:279.
60. Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV. Myeloid dendritic cells: Development, functions, and role in atherosclerotic inflammation. Immunobiology 2015;220:833-44.
61. Chistiakov DA, Sobenin IA, Orekhov AN. Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. Drug Deliv 2012;19:392-405.
62. Soldatov VO, Malorodova TN, Balamutova TI, Ksenofontov AO, Dovgan AP, Urozhevskaya ZS. Endothelial dysfunction: comparative evaluation of ultrasound dopplerography, laser dopplerflowmetry and direct monitoring of arterial pressure for conducting pharmacological tests in rats. Research Results in Pharmacology 2018;4:73-80.
63. Scioli MG, Storti G, D'Amico F, et al. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J Clin Med 2020;9:1995.
64. Rodger CE, McWilliams TG, Ganley IG. Mammalian mitophagy - from in vitro molecules to in vivo models. FEBS J 2018;285:1185-202.
65. Iorio R, Celenza G, Petricca S. Mitophagy: molecular mechanisms, new concepts on parkin activation and the emerging role of AMPK/ULK1 axis. Cells 2021;11:30.
66. Vincow ES, Merrihew G, Thomas RE, et al. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc Natl Acad Sci USA 2013;110:6400-5.
67. Kondapalli C, Kazlauskaite A, Zhang N, et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol 2012;2:120080.
68. Lee L, Seager R, Nakamura Y, Wilkinson KA, Henley JM. Parkin-mediated ubiquitination contributes to the constitutive turnover of mitochondrial fission factor (Mff). PLoS One 2019;14:e0213116.
69. Koyano F, Yamano K, Kosako H, Tanaka K, Matsuda N. Parkin recruitment to impaired mitochondria for nonselective ubiquitylation is facilitated by MITOL. J Biol Chem 2019;294:10300-14.
70. Vives-Bauza C, de Vries RL, Tocilescu M, Przedborski S. PINK1/Parkin direct mitochondria to autophagy. Autophagy 2010;6:315-6.
71. Lazarou M. Keeping the immune system in check: a role for mitophagy. Immunol Cell Biol 2015;93:3-10.
72. Stockum S, Marchesan E, Ziviani E. Mitochondrial quality control beyond PINK1/Parkin. Oncotarget 2018;9:12550-1.
73. Fu M, St-Pierre P, Shankar J, Wang PT, Joshi B, Nabi IR. Regulation of mitophagy by the Gp78 E3 ubiquitin ligase. Mol Biol Cell 2013;24:1153-62.
74. Ikeda F. Mitophagy is induced by short ubiquitin chains on mitochondria. J Cell Biol 2020;219:e202008031.
75. Gatica D, Lahiri V, Klionsky DJ. Cargo recognition and degradation by selective autophagy. Nat Cell Biol 2018;20:233-42.
76. Montava-Garriga L, Ganley IG. Outstanding questions in mitophagy: what we do and do not know. J Mol Biol 2020;432:206-30.
77. Chu CT, Ji J, Dagda RK, et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat Cell Biol 2013;15:1197-205.
78. Chu CT, Bayır H, Kagan VE. LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons: implications for Parkinson disease. Autophagy 2014;10:376-8.
79. Pizzuto M, Pelegrin P. Cardiolipin in immune signaling and cell death. Trends Cell Biol 2020;30:892-903.
80. Singh F, Prescott AR, Rosewell P, Ball G, Reith AD, Ganley IG. Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice. Elife 2021;10:e67604.
81. McWilliams TG, Prescott AR, Montava-Garriga L, et al. Basal mitophagy occurs independently of PINK1 in mouse tissues of high metabolic demand. Cell Metab 2018;27:439-449.e5.
82. Cummins N, Götz J. Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo? Cell Mol Life Sci 2018;75:1151-62.
83. Lee JJ, Sanchez-Martinez A, Martinez Zarate A, et al. Basal mitophagy is widespread in Drosophila but minimally affected by loss of Pink1 or parkin. J Cell Biol 2018;217:1613-22.
84. Matsuda S, Nakanishi A, Minami A, Wada Y, Kitagishi Y. Functions and characteristics of PINK1 and Parkin in cancer. Front Biosci (Landmark Ed) 2015;20:491-501.
85. Quinn PMJ, Moreira PI, Ambrósio AF, Alves CH. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathol Commun 2020;8:189.
86. Ge P, Dawson VL, Dawson TM. PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease. Mol Neurodegener 2020;15:20.
87. Li J, Xu X, Huang H, et al. Pink1 promotes cell proliferation and affects glycolysis in breast cancer. Exp Biol Med (Maywood) 2022;247:985-95.
88. McWilliams TG, Prescott AR, Allen GF, et al. mito-QC illuminates mitophagy and mitochondrial architecture in vivo. J Cell Biol 2016;214:333-45.
89. Whitworth AJ, Pallanck LJ. PINK1/Parkin mitophagy and neurodegeneration-what do we really know in vivo? Curr Opin Genet Dev 2017;44:47-53.
90. Sekine S, Youle RJ. PINK1 import regulation; a fine system to convey mitochondrial stress to the cytosol. BMC Biol 2018;16:2.
91. Lin XH, Qiu BQ, Ma M, et al. Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia. Oncogenesis 2020;9:67.
92. Schweers RL, Zhang J, Randall MS, et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A 2007;104:19500-5.
93. Sandoval H, Thiagarajan P, Dasgupta SK, et al. Essential role for Nix in autophagic maturation of erythroid cells. Nature 2008;454:232-5.
94. Al Rawi S, Louvet-Vallée S, Djeddi A, et al. Postfertilization autophagy of sperm organelles prevents paternal mitochondrial DNA transmission. Science 2011;334:1144-7.
95. Sato M, Sato K. Degradation of paternal mitochondria by fertilization-triggered autophagy in C. elegans embryos. Science 2011;334:1141-4.
96. Rojansky R, Cha MY, Chan DC. Elimination of paternal mitochondria in mouse embryos occurs through autophagic degradation dependent on PARKIN and MUL1. Elife 2016;5:e17896.
97. Gottlieb RA, Stotland A. MitoTimer: a novel protein for monitoring mitochondrial turnover in the heart. J Mol Med (Berl) 2015;93:271-8.
98. Esteban-Martínez L, Sierra-Filardi E, Boya P. Mitophagy, metabolism, and cell fate. Mol Cell Oncol 2017;4:e1353854.
99. Suárez-Rivero JM, Pastor-Maldonado CJ, Povea-Cabello S, et al. From mitochondria to atherosclerosis: the inflammation path. Biomedicines 2021;9:258.
100. Summerhill VI, Grechko AV, Yet SF, Sobenin IA, Orekhov AN. The atherogenic role of circulating modified lipids in atherosclerosis. Int J Mol Sci 2019;20:3561.
101. Georgakopoulos ND, Wells G, Campanella M. The pharmacological regulation of cellular mitophagy. Nat Chem Biol 2017;13:136-46.
102. Wang Y, Nartiss Y, Steipe B, McQuibban GA, Kim PK. ROS-induced mitochondrial depolarization initiates PARK2/PARKIN-dependent mitochondrial degradation by autophagy. Autophagy 2012;8:1462-76.
103. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010;8:e1000298.
104. Bestman JE, Stackley KD, Rahn JJ, Williamson TJ, Chan SS. The cellular and molecular progression of mitochondrial dysfunction induced by 2,4-dinitrophenol in developing zebrafish embryos. Differentiation 2015;89:51-69.
105. Geisler JG, Marosi K, Halpern J, Mattson MP. DNP, mitochondrial uncoupling, and neuroprotection: a little dab’ll do ya. Alzheimers Dement 2017;13:582-91.
106. Tai Y, Li L, Peng X, et al. Mitochondrial uncoupler BAM15 inhibits artery constriction and potently activates AMPK in vascular smooth muscle cells. Acta Pharm Sin B 2018;8:909-18.
107. Dang CP, Issara-Amphorn J, Charoensappakit A, et al. BAM15, a mitochondrial uncoupling agent, attenuates inflammation in the lps injection mouse model: an adjunctive anti-inflammation on macrophages and hepatocytes. J Innate Immun 2021;13:359-75.
108. Felber SM, Brand MD. Valinomycin can depolarize mitochondria in intact lymphocytes without increasing plasma membrane potassium fluxes. FEBS Letters 1982;150:122-4.
109. Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ 2013;20:31-42.
110. Rakovic A, Ziegler J, Mårtensson CU, et al. PINK1-dependent mitophagy is driven by the UPS and can occur independently of LC3 conversion. Cell Death Differ 2019;26:1428-41.
111. Kim KY, Yu SN, Lee SY, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun 2011;413:80-6.
112. Managò A, Leanza L, Carraretto L, et al. Early effects of the antineoplastic agent salinomycin on mitochondrial function. Cell Death Dis 2015;6:e1930.
113. Thomas RE, Andrews LA, Burman JL, Lin WY, Pallanck LJ. PINK1-Parkin pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix. PLoS Genet 2014;10:e1004279.
114. Shi G, Lee JR, Grimes DA, et al. Functional alteration of PARL contributes to mitochondrial dysregulation in Parkinson’s disease. Hum Mol Genet 2011;20:1966-74.
115. Meissner C, Lorenz H, Hehn B, Lemberg MK. Intramembrane protease PARL defines a negative regulator of PINK1- and PARK2/Parkin-dependent mitophagy. Autophagy 2015;11:1484-98.
116. Shi G, McQuibban GA. The mitochondrial rhomboid protease PARL is regulated by PDK2 to integrate mitochondrial quality control and metabolism. Cell Rep 2017;18:1458-72.
117. Lysyk L, Brassard R, Arutyunova E, et al. Insights into the catalytic properties of the mitochondrial rhomboid protease PARL. J Biol Chem 2021;296:100383.
118. Urban S, Dickey SW. The rhomboid protease family: a decade of progress on function and mechanism. Genome Biol 2011;12:231.
119. Parsons WH, Rutland NT, Crainic JA, et al. Development of succinimide-based inhibitors for the mitochondrial rhomboid protease PARL. Bioorg Med Chem Lett 2021;49:128290.
120. Hertz NT, Berthet A, Sos ML, et al. A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell 2013;154:737-47.
121. Clark EH, Vázquez de la Torre A, Hoshikawa T, Briston T. Targeting mitophagy in Parkinson’s disease. J Biol Chem 2021;296:100209.
122. Nagaria O, Singh S, Kabir R, Kobayashi S, Kobayashi T, Liang Q. Kinetin is sufficient to accelerate mitophagy flux in H9c2 cardiac myoblast cells. FASEB j 2019:33.
123. Allen GF, Toth R, James J, Ganley IG. Loss of iron triggers PINK1/Parkin-independent mitophagy. EMBO Rep 2013;14:1127-35.
124. Lee JW, Ko J, Ju C, Eltzschig HK. Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med 2019;51:1-13.
125. Zhao JF, Rodger CE, Allen GFG, Weidlich S, Ganley IG. HIF1α-dependent mitophagy facilitates cardiomyoblast differentiation. Cell Stress 2020;4:99-113.
126. Park SJ, Shin JH, Kim ES, et al. Mitochondrial fragmentation caused by phenanthroline promotes mitophagy. FEBS Lett 2012;586:4303-10.
127. Hara Y, Yanatori I, Tanaka A, et al. Iron loss triggers mitophagy through induction of mitochondrial ferritin. EMBO Rep 2020;21:e50202.
128. Xu LJ, Jin L, Pan H, et al. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacol Sin 2006;27:1333-9.
129. Denison SR, Wang F, Becker NA, et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 2003;22:8370-8.
130. Long M, Sanchez-Martinez A, Longo M, et al. DGAT1 activity synchronises with mitophagy to protect cells from metabolic rewiring by iron depletion. EMBO J 2022;41:e109390.
131. Read AD, Bentley RE, Archer SL, Dunham-Snary KJ. Mitochondrial iron-sulfur clusters: Structure, function, and an emerging role in vascular biology. Redox Biol 2021;47:102164.
132. Paul BT, Manz DH, Torti FM, Torti SV. Mitochondria and Iron: current questions. Expert Rev Hematol 2017;10:65-79.
133. Ward DM, Cloonan SM. Mitochondrial iron in human health and disease. Annu Rev Physiol 2019;81:453-82.
136. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017;60:1577-85.
137. Bhansali S, Bhansali A, Dhawan V. Metformin promotes mitophagy in mononuclear cells: a potential in vitro model for unraveling metformin’s mechanism of action. Ann N Y Acad Sci 2020;1463:23-36.
138. Pan H, Finkel T. Key proteins and pathways that regulate lifespan. J Biol Chem 2017;292:6452-60.
139. Jang SY, Kang HT, Hwang ES. Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J Biol Chem 2012;287:19304-14.
140. Sebori R, Kuno A, Hosoda R, Hayashi T, Horio Y. Resveratrol decreases oxidative stress by restoring mitophagy and improves the pathophysiology of dystrophin-deficient mdx mice. Oxid Med Cell Longev 2018;2018:9179270.
141. Shaito A, Posadino AM, Younes N, et al. Potential adverse effects of resveratrol: a literature review. Int J Mol Sci 2020;21:2084.
143. Jia S, Xu X, Zhou S, Chen Y, Ding G, Cao L. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Cell Death Dis 2019;10:142.
144. Hung CH, Chan SH, Chu PM, Tsai KL. Quercetin is a potent anti-atherosclerotic compound by activation of SIRT1 signaling under oxLDL stimulation. Mol Nutr Food Res 2015;59:1905-17.
145. Li X, Wang H, Gao Y, et al. Protective effects of quercetin on mitochondrial biogenesis in experimental traumatic brain injury via the Nrf2 signaling pathway. PLoS One 2016;11:e0164237.
146. Liu T, Yang Q, Zhang X, et al. Quercetin alleviates kidney fibrosis by reducing renal tubular epithelial cell senescence through the SIRT1/PINK1/mitophagy axis. Life Sci 2020;257:118116.
147. Pietrocola F, Castoldi F, Markaki M, et al. Aspirin recapitulates features of caloric restriction. Cell Rep 2018;22:2395-407.
148. Eisenberg T, Knauer H, Schauer A, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 2009;11:1305-14.
